Oric Pharmaceuticals, Inc.

treasury securities, certificates of deposit and high-quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2025.

SEC original ↗Oric Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Enozertinib (formerly ORIC-114): a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations • Continue to enroll Phase 1b trial of enozertinib as a single-agent in patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations, including patients with CNS metastases that are either treated or untreated but asymptomatic, across our 2L+ dose optimization cohorts and 1L expansion cohorts.

SEC original ↗Oric Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

• Announced strategic pipeline prioritization to focus operational and financial resources on the continued advancement of the two lead clinical programs, ORIC-944 and enozertinib.

SEC original ↗Oric Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

This initiative will result in the elimination of the discovery research group with a corresponding 20% workforce reduction.

SEC original ↗Oric Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

• As a result of the strategic pipeline prioritization, cash runway is expected to fund the revised operating plan into 2H 2028 (previously 2H 2027), which is beyond anticipated primary endpoint readouts from the first Phase 3 trials for ORIC-944 and enozertinib.

SEC original ↗Oric Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Legal Proceedings 20 Item 1A.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

These forward-looking statements speak only as of the date of this quarterly report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this quarterly report on Form 10-Q.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Mirati may terminate the agreement if the Company challenges any of the patent rights licensed to the Company by Mirati or it discontinues development of licensed products for a specified period of time.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled Special Note Regarding Forward-Looking Statements.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026

Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion.

SEC original ↗Oric Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 3, 2026